Literature DB >> 7892197

Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty.

L Laue1, W Y Chan, A J Hsueh, M Kudo, S Y Hsu, S M Wu, L Blomberg, G B Cutler.   

Abstract

Genomic DNA from 32 unrelated families with male-limited precocious puberty was examined for the previously described Asp-578-->Gly, Met-571-->Ile, and Thr-577-->Ile mutations in transmembrane helix 6 of the human luteinizing hormone receptor (hLHR). Twenty-eight families had the inherited form of the disorder, and of these, 24 were found to have the Asp-578-->Gly mutation. Four additional mutations were found among the remaining four families with the inherited form and in four sporadic cases of the disorder: an A-->C transversion resulting in substitution of leucine for Ile-542 in the fifth transmembrane helix, an A-->G transition resulting in substitution of glycine for Asp-564 in the third cytoplasmic loop, a G-->T transversion resulting in substitution of tyrosine for Asp-578 in the sixth transmembrane helix, and a T-->C transition resulting in substitution of arginine for Cys-581 in the sixth transmembrane helix. Human embryonic kidney cells transfected with cDNAs for each of the mutant hLHRs, created by PCR-based mutagenesis of the wild-type hLHR cDNA, exhibited increased levels of basal cAMP production in the absence of agonist, indicating constitutive activation of the mutation hLHRs. Three of the additional mutations had specific features: Ile-542-->Leu and Cys-581-->Arg appeared ligand-unresponsive, whereas Asp-578-->Tyr appeared to correlate genotype with phenotype. We conclude that the region spanning nt 1624-1741 of exon 11 is a hotspot for heterogeneous point mutations that constitutively activate the hLHR and cause male-limited precocious puberty.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7892197      PMCID: PMC42391          DOI: 10.1073/pnas.92.6.1906

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty.

Authors:  A Shenker; L Laue; S Kosugi; J J Merendino; T Minegishi; G B Cutler
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

2.  Treatment of familial male precocious puberty with spironolactone and testolactone.

Authors:  L Laue; D Kenigsberg; O H Pescovitz; K D Hench; K M Barnes; D L Loriaux; G B Cutler
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

3.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

4.  Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty.

Authors:  H Kremer; E Mariman; B J Otten; G W Moll; G B Stoelinga; J M Wit; M Jansen; S L Drop; B Faas; H H Ropers
Journal:  Hum Mol Genet       Date:  1993-11       Impact factor: 6.150

5.  Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation.

Authors:  M R Pollak; E M Brown; H L Estep; P N McLaine; O Kifor; J Park; S C Hebert; C E Seidman; J G Seidman
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

6.  Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.

Authors:  L Duprez; J Parma; J Van Sande; A Allgeier; J Leclère; C Schvartz; M J Delisle; M Decoulx; J Orgiazzi; J Dumont
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

7.  Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases.

Authors:  S M Rosenthal; M M Grumbach; S L Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

8.  Hazards of ketoconazole therapy in testotoxicosis.

Authors:  D Babovic-Vuksanovic; M D Donaldson; N A Gibson; A M Wallace
Journal:  Acta Paediatr       Date:  1994-09       Impact factor: 2.299

9.  Testicular leydig cell hyperplasia as a cause of familial sexual precocity.

Authors:  H K Schedewie; E O Reiter; I Z Beitins; S Seyed; V D Wooten; J F Jimenez; E J Aiman; G W DeVane; J F Redman; M J Elders
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

10.  Vasoactive intestinal peptide: a novel stimulator of steroidogenesis by cultured rat granulosa cells.

Authors:  J B Davoren; A J Hsueh
Journal:  Biol Reprod       Date:  1985-08       Impact factor: 4.285

View more
  36 in total

Review 1.  Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors.

Authors:  A C Latronico; D L Segaloff
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

Review 2.  Structural organization of G-protein-coupled receptors.

Authors:  A L Lomize; I D Pogozheva; H I Mosberg
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

3.  Revisiting and questioning functional rescue between dimerized LH receptor mutants.

Authors:  Meilin Zhang; Rongbin Guan; Deborah L Segaloff
Journal:  Mol Endocrinol       Date:  2012-03-08

Review 4.  Transgenic models for exploring gonadotropin biology in the male.

Authors:  Charles M Allan; David J Handelsman
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

5.  Mutation analysis of the LH receptor gene in Leydig cell adenoma and hyperplasia and functional and biochemical studies of activating mutations of the LH receptor gene.

Authors:  Annemieke M Boot; Serge Lumbroso; Miriam Verhoef-Post; Annette Richter-Unruh; Leendert H J Looijenga; Ada Funaro; Auke Beishuizen; André van Marle; Stenvert L S Drop; Axel P N Themmen
Journal:  J Clin Endocrinol Metab       Date:  2011-04-13       Impact factor: 5.958

Review 6.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

Review 7.  Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors.

Authors:  P J Pauwels; T Wurch
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

Review 8.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

9.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

10.  Synthesis and characterization of a novel retinylamine analog inhibitor of constitutively active rhodopsin mutants found in patients with autosomal dominant retinitis pigmentosa.

Authors:  T Yang; B B Snider; D D Oprian
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.